Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ: CCCC )

5.790 -0.205 (-3.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 999,233
Open 6.190
Bid (Size) 4.600 (1)
Ask (Size) 5.780 (1)
Prev. Close 5.995
Today's Range 5.590 - 6.210
52wk Range 1.060 - 11.88
Shares Outstanding 48,797,226
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CCCC Stock Earnings: C4 Therapeutics Beats EPS, Beats Revenue for Q2 2024
CCCC stock results show that C4 Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-11.20%
-11.20%
1 Month
+30.70%
+30.70%
3 Month
-14.73%
-14.73%
6 Month
+3.21%
+3.21%
1 Year
+64.49%
+64.49%

More News

Read More
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
From C4 Therapeutics, Inc.
Via GlobeNewswire
Key Takeaways From C4 Therapeutics Analyst Ratings
Via Benzinga
Breaking Down C4 Therapeutics: 4 Analysts Share Their Views
Via Benzinga
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
From C4 Therapeutics, Inc.
Via GlobeNewswire
CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations For C4 Therapeutics's Future
Via Benzinga
C4 Therapeutics Inc. (NASDAQ: CCCC) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Capital One Financial To Acquire Discover, Joins SSR Mining And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
Via InvestorPlace
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
MarketBeat Week in Review – 12/18 - 12/22
Via MarketBeat
Topics Economy
Exposures Interest Rates
C4 Therapeutics blasts off: what's next?
Via MarketBeat
Topics ETFs
C4 Therapeutics Inc. (NASDAQ: CCCC) Near Top of Volume Charts in Friday Trading
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.